Chimeric Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2020
Operating Revenue	3.97	-	-	-	-	Upgrade
Other Revenue	8.72	7.46	4.51	2.62	-	Upgrade
Revenue	12.68	7.46	4.51	2.62	-	Upgrade
Revenue Growth (YoY)	70.09%	65.52%	72.16%	-	-	Upgrade
Cost of Revenue	0.85	-	-	-	-	Upgrade
Gross Profit	11.84	7.46	4.51	2.62	-	Upgrade
Selling, General & Admin	6.45	9	11.73	7.9	8.97	Upgrade
Research & Development	10.79	10.19	14.43	6.12	3.78	Upgrade
Operating Expenses	18.33	19.76	29.49	17.19	14.85	Upgrade
Operating Income	-6.49	-12.31	-24.98	-14.57	-14.85	Upgrade
Interest Expense	-0.21	-0.33	-0.77	-0.64	-0.01	Upgrade
Interest & Investment Income	0.05	0.12	0.03	0.01	0	Upgrade
Currency Exchange Gain (Loss)	-0.11	0.06	-0.09	-0.53	-0.26	Upgrade
Other Non Operating Income (Expenses)	-	0.9	-	-	0	Upgrade
EBT Excluding Unusual Items	-6.77	-11.56	-25.82	-15.73	-15.11	Upgrade
Gain (Loss) on Sale of Assets	-0	-0	-0	-0	-	Upgrade
Other Unusual Items	-3.55	-0.96	-	-	-	Upgrade
Pretax Income	-10.32	-12.52	-25.82	-15.73	-15.11	Upgrade
Income Tax Expense	0.11	0.01	0.09	0.16	-	Upgrade
Net Income	-10.43	-12.53	-25.92	-15.9	-15.11	Upgrade
Net Income to Common	-10.43	-12.53	-25.92	-15.9	-15.11	Upgrade
Shares Outstanding (Basic)	1,352	696	433	360	182	Upgrade
Shares Outstanding (Diluted)	1,352	696	433	360	182	Upgrade
Shares Change (YoY)	94.34%	60.57%	20.37%	97.88%	-	Upgrade
EPS (Basic)	-0.01	-0.02	-0.06	-0.04	-0.08	Upgrade
EPS (Diluted)	-0.01	-0.02	-0.06	-0.04	-0.08	Upgrade
Free Cash Flow	-7.28	-7.54	-16.31	-13.17	-8.85	Upgrade
Free Cash Flow Per Share	-0.01	-0.01	-0.04	-0.04	-0.05	Upgrade
Gross Margin	93.32%	100.00%	100.00%	100.00%	-	Upgrade
Operating Margin	-51.14%	-165.01%	-554.44%	-556.82%	-	Upgrade
Profit Margin	-82.23%	-168.01%	-575.20%	-607.48%	-	Upgrade
Free Cash Flow Margin	-57.36%	-101.07%	-361.89%	-503.04%	-	Upgrade
EBITDA	-5.46	-11.22	-24.02	-13.62	-14	Upgrade
EBITDA Margin	-43.01%	-150.50%	-	-	-	Upgrade
D&A For EBITDA	1.03	1.08	0.97	0.95	0.85	Upgrade
EBIT	-6.49	-12.31	-24.98	-14.57	-14.85	Upgrade
EBIT Margin	-51.14%	-165.01%	-	-	-	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.